Completed PHASE2 INTERVENTIONAL 1-arm NCT00453895

Sunitinib in Refractory Adrenocortical Carcinoma (SIRAC)

Sunitinib in Refractory Adrenocortical-Carcinoma Patients Progressing After Cytotoxic Chemotherapy

Sponsor: Pfizer

Interventions Sunitinib

Updated 10 times since 2017 Last updated: Aug 25, 2018 Started: Jul 31, 2007 Primary completion: Aug 31, 2011 Completion: Feb 29, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Adrenocortical Carcinoma, this trial is completed. The trial is conducted by Pfizer and has accumulated 10 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2

▶ Show 5 earlier versions

Dec 2021 — Dec 2022 [monthly]

Completed PHASE2
Jan 2021 — Dec 2021 [monthly]

Completed PHASE2
Feb 2019 — Jan 2021 [monthly]

Completed PHASE2

Status: Unknown Status → Completed
Jun 2018 — Feb 2019 [monthly]

Unknown Status PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Jul 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer
University of Wuerzburg

Data source: University of Wuerzburg

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Berlin, Germany
• Würzburg, Germany